New biomaterials for the sustained release of nitric oxide: Past, present and future

Adam Friedman, Joel M. Friedman

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Nitric oxide (NO), the 1992 'Molecule of the Year', is the focus of immense medical and scientific exploration. Interest in NO has grown exponentially since the initial and relatively recent discovery that NO is the long sought after endothelial relaxing factor. There is intense research that is continuing to expose the extensive physiologic impact of NO in virtually all organ and tissue systems under both normal and pathological conditions. Both the rate of delivery and the amount of site-specific generated NO modulate a balance between cytoregulatory and cytotoxic activities. This balancing act and the very short lifetime of NO under physiological conditions pose an extreme challenge with respect to harnessing the exceptional therapeutic potential of this molecule. Over the past two decades, the race to translate the therapeutic potential of NO to the bedside has been overwhelmingly through the development of numerous NO delivery devices/vehicles. So far no one product has emerged as a clearcut winner. This review: discusses and evaluates NO-donating platforms that are available at present; attempts to enhance delivery and efficacy through encapsulation in silane-based hydrogel matrices; and discusses and evaluates the future direction of these advances.

Original languageEnglish (US)
Pages (from-to)1113-1122
Number of pages10
JournalExpert Opinion on Drug Delivery
Volume6
Issue number10
DOIs
StatePublished - Oct 2009

Fingerprint

Biocompatible Materials
Nitric Oxide
Silanes
Hydrogel
Equipment and Supplies
Therapeutics
Research

Keywords

  • Drug delivery
  • Nanotechnology
  • Nitric oxide
  • Sol-gel

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

New biomaterials for the sustained release of nitric oxide : Past, present and future. / Friedman, Adam; Friedman, Joel M.

In: Expert Opinion on Drug Delivery, Vol. 6, No. 10, 10.2009, p. 1113-1122.

Research output: Contribution to journalArticle

@article{db4c716f0018415eb721f9c6b19c9f06,
title = "New biomaterials for the sustained release of nitric oxide: Past, present and future",
abstract = "Nitric oxide (NO), the 1992 'Molecule of the Year', is the focus of immense medical and scientific exploration. Interest in NO has grown exponentially since the initial and relatively recent discovery that NO is the long sought after endothelial relaxing factor. There is intense research that is continuing to expose the extensive physiologic impact of NO in virtually all organ and tissue systems under both normal and pathological conditions. Both the rate of delivery and the amount of site-specific generated NO modulate a balance between cytoregulatory and cytotoxic activities. This balancing act and the very short lifetime of NO under physiological conditions pose an extreme challenge with respect to harnessing the exceptional therapeutic potential of this molecule. Over the past two decades, the race to translate the therapeutic potential of NO to the bedside has been overwhelmingly through the development of numerous NO delivery devices/vehicles. So far no one product has emerged as a clearcut winner. This review: discusses and evaluates NO-donating platforms that are available at present; attempts to enhance delivery and efficacy through encapsulation in silane-based hydrogel matrices; and discusses and evaluates the future direction of these advances.",
keywords = "Drug delivery, Nanotechnology, Nitric oxide, Sol-gel",
author = "Adam Friedman and Friedman, {Joel M.}",
year = "2009",
month = "10",
doi = "10.1517/17425240903196743",
language = "English (US)",
volume = "6",
pages = "1113--1122",
journal = "Expert Opinion on Drug Delivery",
issn = "1742-5247",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - New biomaterials for the sustained release of nitric oxide

T2 - Past, present and future

AU - Friedman, Adam

AU - Friedman, Joel M.

PY - 2009/10

Y1 - 2009/10

N2 - Nitric oxide (NO), the 1992 'Molecule of the Year', is the focus of immense medical and scientific exploration. Interest in NO has grown exponentially since the initial and relatively recent discovery that NO is the long sought after endothelial relaxing factor. There is intense research that is continuing to expose the extensive physiologic impact of NO in virtually all organ and tissue systems under both normal and pathological conditions. Both the rate of delivery and the amount of site-specific generated NO modulate a balance between cytoregulatory and cytotoxic activities. This balancing act and the very short lifetime of NO under physiological conditions pose an extreme challenge with respect to harnessing the exceptional therapeutic potential of this molecule. Over the past two decades, the race to translate the therapeutic potential of NO to the bedside has been overwhelmingly through the development of numerous NO delivery devices/vehicles. So far no one product has emerged as a clearcut winner. This review: discusses and evaluates NO-donating platforms that are available at present; attempts to enhance delivery and efficacy through encapsulation in silane-based hydrogel matrices; and discusses and evaluates the future direction of these advances.

AB - Nitric oxide (NO), the 1992 'Molecule of the Year', is the focus of immense medical and scientific exploration. Interest in NO has grown exponentially since the initial and relatively recent discovery that NO is the long sought after endothelial relaxing factor. There is intense research that is continuing to expose the extensive physiologic impact of NO in virtually all organ and tissue systems under both normal and pathological conditions. Both the rate of delivery and the amount of site-specific generated NO modulate a balance between cytoregulatory and cytotoxic activities. This balancing act and the very short lifetime of NO under physiological conditions pose an extreme challenge with respect to harnessing the exceptional therapeutic potential of this molecule. Over the past two decades, the race to translate the therapeutic potential of NO to the bedside has been overwhelmingly through the development of numerous NO delivery devices/vehicles. So far no one product has emerged as a clearcut winner. This review: discusses and evaluates NO-donating platforms that are available at present; attempts to enhance delivery and efficacy through encapsulation in silane-based hydrogel matrices; and discusses and evaluates the future direction of these advances.

KW - Drug delivery

KW - Nanotechnology

KW - Nitric oxide

KW - Sol-gel

UR - http://www.scopus.com/inward/record.url?scp=70349383201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349383201&partnerID=8YFLogxK

U2 - 10.1517/17425240903196743

DO - 10.1517/17425240903196743

M3 - Article

C2 - 19663720

AN - SCOPUS:70349383201

VL - 6

SP - 1113

EP - 1122

JO - Expert Opinion on Drug Delivery

JF - Expert Opinion on Drug Delivery

SN - 1742-5247

IS - 10

ER -